Progression versus regression of chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 21, Issue 2, 2006, Pages 281-284

  Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ACEI, angiotensin; ARB; Capillary branching; PAI 1; Podocyte

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULOTROPIN; VASCULOTROPIN A;

BLOOD PRESSURE; CAPILLARY; CELL INTERACTION; CHRONIC KIDNEY DISEASE; DATA ANALYSIS; DISEASE COURSE; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; FEASIBILITY STUDY; GLOMERULOSCLEROSIS; HUMAN; KIDNEY CELL; KIDNEY PARENCHYMA; NEPHRECTOMY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; REMISSION; RENOVASCULAR HYPERTENSION; REVIEW; SCLEROSIS;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; REMISSION INDUCTION;

EID: 31544434502     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi291     Document Type: Review

References (25)

1. Fogo A. Progression and potential regression of glomerulosclerosis. Nephrology Forum. Kidney Int 2001; 59: 804-819
2. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991; 40: 195-202
3. Marinides GN, Groggel GC, Cohen AH, Border WA. Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 1990; 37: 749-757
4. Adamczak M, Gross ML, Krtil J et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14: 2833-2842
5. Adamczak M, Gross ML, Amann K, Ritz E. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 2004; 15: 3063-3072
6. Zoja C, Corna D, Zoja C et al. How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 2002; 13: 2898-2908
7. Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005; 67: 1913-1924
8. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: Role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14: 1132-1144
9. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005; 16: 966-976
10. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 1219-1227
11. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol 2002; 283: F209-F220
12. Matsuo S, Lopez-Guisa JM, Cai X et al. Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005; 67: 2221-2228
13. Aldigier JC, Kanjanabuch T, Ma L-J, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314
14. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-344
15. Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2003; 88: 3867-3873
16. Xu BJ, Shyr Y, Liang X et al. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 2005; 16: 2967-2975
17. Scruggs B, Donnert E, Ma LJ, Bertram J, Fogo AB. Capillary branching in regression of glomerulosclerosis [abstract]. J Am Soc Nephrol 2005; 16: 674A
18. Wahl EM, Quintas LV, Lurie LL, Gargano ML. A graph theory analysis of renal glomerular microvascular networks. Microvasc Res 2004; 67: 223-230
19. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716
20. Satchell SC, Mathieson PW. Angiopoietins: Microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol 2003; 16: 168-178
21. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12: 1448-1457
22. Liang X, Ma L-J, Madaio M, Zent R, Pozzi A, Fogo AB. Podocyte injury decreases and angiotensin type 1 receptor blocker (ARB) restores glomerular endothelial cell (GEN) angiogenesis and proliferation [abstract]. J Am Soc Nephrol 2004; 15: 485A-486A
23. Marcussen N, Nyengaard JR, Christensen S. Compensatory growth of glomeruli is accomplished by an increased number of glomerular capillaries. Lab Invest 1994; 70: 868-874
24. Akaoka K, White RHR, Raafat F. Glomerular morphometry in childhood reflux nephropathy, emphasizing the capillary changes. Kidney Int 1995; 47: 1108-1114
25. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75